Op-Ed: New Alzheimer’s Drug Is a Problem for FDA’s Pass-Fail Approach

HOME/Commentary & Opinion/Op-Ed: New Alzheimer’s Drug Is a Problem for FDA’s Pass-Fail Approach

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

About PORTAL
Our Team
Our Work
Careers
Contact

Privacy Policy
Terms of Use
Cookie Policy
Consent Preferences